146 related articles for article (PubMed ID: 8195641)
21. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
22. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
23. m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer.
Pullyblank AM; Guillou PJ; Monson JR
Br J Cancer; 1994 Oct; 70(4):753-8. PubMed ID: 7917934
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
25. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
26. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Tsang KY; Finch MD; Primus FJ; Schlom J
Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
[TBL] [Abstract][Full Text] [Related]
27. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
28. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY
Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
[TBL] [Abstract][Full Text] [Related]
30. Development and functional characterization of a murine/human chimeric antibody with specificity for the human interleukin-2 receptor.
Vandevyver C; Steukers M; Lambrechts J; Heyligen H; Raus J
Mol Immunol; 1993 Jul; 30(10):865-76. PubMed ID: 8341281
[TBL] [Abstract][Full Text] [Related]
31. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
32. Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12.
Flieger D; Spengler U; Beier I; Kleinschmidt R; Sauerbruch T; Schmidt-Wolf IG
J Immunother; 2000; 23(4):480-6. PubMed ID: 10916758
[TBL] [Abstract][Full Text] [Related]
33. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.
Masucci G; Wersäll P; Nielsen J; Nielsen HK; Wigzell H; Mellstedt H
Hybridoma; 1989 Oct; 8(5):507-16. PubMed ID: 2807310
[TBL] [Abstract][Full Text] [Related]
34. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
Rosales C; Jeglum KA; Obrocka M; Steplewski Z
Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
[TBL] [Abstract][Full Text] [Related]
35. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
Weiner LM; Zarou CM; O'Brien J; Ring D
J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
[TBL] [Abstract][Full Text] [Related]
36. Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.
Nishihara T; Sawada T; Yamamoto A; Yamashita Y; Ho JJ; Kim YS; Chung KH
Jpn J Cancer Res; 2000 Aug; 91(8):817-24. PubMed ID: 10965023
[TBL] [Abstract][Full Text] [Related]
37. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.
Tempero MA; Haga Y; Sivinski C; Steplewski Z; Kay HD; Pour P
Int J Pancreatol; 1991; 9():125-34. PubMed ID: 1744438
[TBL] [Abstract][Full Text] [Related]
39. Antitumour activity of a chimeric antibody against the leucocyte antigen CD48.
Sun H; Biggs JC; Smith GM
Cancer Immunol Immunother; 2000 Jan; 48(10):595-602. PubMed ID: 10630312
[TBL] [Abstract][Full Text] [Related]
40. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
